Key result
Novel biomarkers like troponins and natriuretic peptides enhance diagnosis and prognosis in HF and AMI.
Why the study?
Numerous biomarkers pertaining to cardiovascular diagnosis, prognosis, and risk prediction have been identified, but few have made their way to clinical practice.
Design
Review
Authors
Loading...
Reinforces troponin and natriuretic peptide roles in HF and AMI; leaves open incremental value of newer biomarkers pending prospective trials.
Key points are not available for this paper at this time.
Lyngbakken et al. (2018) studied this question. Novel cardiovascular biomarkers, such as cardiac troponins and natriuretic peptides, enhance diagnosis and prognosis in heart failure and acute myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: